AQUAVAN® Injection, a Water-soluble Prodrug of Propofol, as a Bolus Injection: A Phase I Dose-escalation Comparison with DIPRIVAN® (Part 1): Pharmacokinetics: Retracted
Ekaterina Gibiansky; Michel M. R. F. Struys; Leonid Gibiansky; Ann L. G. Vanluchene; James Vornov; Eric P. Mortier; Eric Burak; Luc Van Bortel
Author Information: * Head, Pharmacometrics, and Principal Scientist, ∥ Director, Clinical Research, Guilford Pharmaceuticals Inc., Baltimore, Maryland. † Professor in Anesthesia and Research Coordinator, § Staff Anesthesiologist, # Professor in Anesthesia and Chair, Department of Anesthesia, Ghent University Hospital. ‡ Former position: Senior Statistician, Emmes Corporation, Rockville, Maryland. Current position: Principal Scientist, Metrum Research Group, Avon, Connecticut. ** Former position: Director of DMPK, Guilford Pharmaceuticals Inc., Baltimore, Maryland. Current position: Pharmacokineticist, Rib-X Pharmaceuticals, New Haven, Connecticut. †† Professor, Clinical Pharmacology and Pharmacotherapy, Heymans Institute of Pharmacology, Ghent University and Head of Drug Research Unit Ghent, Ghent University Hospital.
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.